Guided Therapeutics Net income (Q1, 2019)-215 K
Guided Therapeutics EBIT (Q1, 2019)-257 K
Guided Therapeutics Cash, 31-Mar-20196 K
Guided Therapeutics EV565.9 K

Guided Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cost of goods sold

611.0k891.0k537.0k493.0k530.0k89.0k

Sales and marketing expense

901.0k1.2m718.0k393.0k245.0k195.0k

R&D expense

2.7m2.8m1.5m733.0k334.0k244.0k

General and administrative expense

3.5m4.6m4.1m2.8m2.3m1.1m

Operating expense total

7.2m8.6m6.3m3.9m2.8m1.5m

EBIT

(6.6m)(8.7m)(6.2m)(3.8m)(3.1m)(1.5m)

Interest expense

45.0k979.0k1.3m1.9m1.1m1.8m

Pre tax profit

1.0m

Income tax expense

Net Income

(7.2m)(9.9m)(6.9m)(4.0m)(10.7m)1.0m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cost of goods sold

117.0k192.0k271.0k260.0k107.0k207.0k230.0k68.0k33.0k85.0k16.0k82.0k97.0k3.0k1.0k1.0k

Sales and marketing expense

249.0k283.0k345.0k135.0k172.0k183.0k187.0k117.0k86.0k92.0k82.0k67.0k37.0k62.0k55.0k39.0k45.0k

R&D expense

596.0k607.0k624.0k892.0k373.0k305.0k413.0k290.0k148.0k87.0k91.0k89.0k69.0k69.0k62.0k43.0k47.0k

General and administrative expense

822.0k1.1m999.0k1.4m963.0k1.0m1.1m917.0k760.0k510.0k346.0k382.0k1.2m246.0k381.0k154.0k182.0k

Operating expense total

1.7m2.0m2.0m2.4m1.5m1.5m1.7m1.3m994.0k689.0k519.0k538.0k1.3m377.0k498.0k236.0k274.0k

EBIT

(1.6m)(1.6m)(2.0m)(2.4m)(1.5m)(1.6m)(1.8m)130.0k(1.9m)(211.0k)(107.0k)(533.0k)(1.3m)(376.0k)(491.0k)(234.0k)(257.0k)

Interest expense

11.0k27.0k47.0k371.0k492.0k323.0k404.0k158.0k1.2m226.0k223.0k325.0k268.0k244.0k296.0k239.0k371.0k

Pre tax profit

(1.4m)(2.2m)(3.0m)(1.2m)(1.7m)(2.2m)(1.1m)(2.4m)1.1m3.4m(746.0k)(215.0k)

Income tax expense

Net Income

(1.4m)(1.6m)(2.2m)(3.0m)(1.2m)(1.7m)(2.2m)130.0k(1.9m)(211.0k)(107.0k)(1.1m)(2.4m)1.1m3.4m(746.0k)(215.0k)

Guided Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

613.0k162.0k35.0k14.0k1.0k

Current Assets

2.0m1.8m2.1m1.0m380.0k196.0k

PP&E

920.0k587.0k318.0k126.0k49.0k21.0k

Total Assets

3.3m3.0m2.6m1.5m489.0k236.0k

Accounts Payable

891.0k1.7m1.8m2.6m3.0m3.0m

Short-term debt

109.0k123.0k783.0k380.0k

Current Liabilities

1.8m4.6m5.5m9.3m11.9m11.0m

Long-term debt

103.0k

Non-Current Liabilities

1.7m2.9m2.6m

Total Debt

212.0k783.0k380.0k

Total Liabilities

3.4m7.5m8.1m10.8m19.9m16.1m

Additional Paid-in Capital

101.8m108.0m114.8m116.4m117.4m118.3m

Retained Earnings

(103.0m)(113.1m)(122.6m)(127.6m)(138.5m)(137.6m)

Total Equity

(5.6m)(19.4m)(15.8m)

Debt to Equity Ratio

0 x

Debt to Assets Ratio

1.6 x

Financial Leverage

-0.5 x0 x0 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

400.0k50.0k485.0k42.0k18.0k2.0m172.0k56.0k22.0k4.0k1.0k8.0k74.0k76.0k41.0k70.0k6.0k

Accounts Receivable

(89.0k)

Inventories

196.0k

Current Assets

1.5m1.5m1.9m2.1m1.6m3.3m2.3m2.0m2.1m1.9m1.1m1.1m830.0k466.0k368.0k447.0k167.0k

PP&E

1.0m807.0k804.0k706.0k515.0k444.0k377.0k264.0k217.0k171.0k89.0k65.0k56.0k43.0k32.0k27.0k16.0k

Total Assets

2.9m2.6m3.8m3.7m2.6m4.0m2.8m2.4m2.3m2.1m1.5m1.5m905.0k527.0k418.0k491.0k404.0k

Accounts Payable

822.0k1.3m1.1m1.7m1.6m2.0m1.5m2.0m2.2m2.5m2.7m2.9m3.0m3.0m3.0m3.0m3.0m

Short-term debt

973.0k1.0m445.0k

Current Liabilities

1.6m2.8m2.5m4.1m5.2m4.8m5.0m6.0m8.0m8.5m9.7m10.8m11.4m12.2m12.6m10.7m11.7m

Long-term debt

1.0m585.0k814.0k905.0k

Non-Current Liabilities

798.0k1.1m3.8m3.5m2.4m2.0m1.3m1.8m

Total Debt

1.0m585.0k814.0k905.0k973.0k1.0m445.0k

Total Liabilities

2.4m3.9m6.3m7.7m6.8m6.3m7.8m9.4m11.9m13.3m18.5m14.6m14.7m16.4m

Additional Paid-in Capital

97.6m102.5m103.6m105.3m108.7m113.0m114.5m115.5m116.2m116.3m116.9m116.8m117.2m117.9m118.2m118.9m117.8m

Retained Earnings

(98.3m)(104.6m)(106.8m)(109.8m)(114.3m)(117.3m)(120.1m)(122.9m)(125.1m)(125.5m)(127.8m)(128.9m)(131.3m)(137.5m)(134.1m)(134.9m)(137.9m)

Total Equity

522.0k(1.3m)(2.5m)(3.9m)(5.0m)(2.7m)(3.5m)(5.4m)(7.1m)(7.3m)(9.1m)(10.3m)(12.3m)(17.9m)(14.2m)(14.2m)(16.0m)

Debt to Equity Ratio

-0.1 x-0.1 x-0.1 x

Debt to Assets Ratio

0.9 x1.7 x2.3 x

Financial Leverage

5.6 x-2 x-1.5 x-0.9 x-0.5 x-1.5 x-0.8 x-0.4 x-0.3 x-0.3 x-0.2 x-0.1 x-0.1 x0 x0 x0 x0 x

Guided Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(7.2m)(9.9m)(6.9m)(4.0m)(10.7m)1.0m

Depreciation and Amortization

461.0k1.1m1.2m213.0k27.0k

Accounts Receivable

(33.0k)129.0k(31.0k)(9.0k)(10.0k)

Inventories

(669.0k)61.0k345.0k508.0k151.0k

Accounts Payable

126.0k1.7m91.0k775.0k420.0k(6.0k)

Cash From Operating Activities

(5.6m)(4.0m)(1.8m)(1.1m)(1.4m)

Cash From Investing Activities

(107.0k)(8.0k)

Cash From Financing Activities

5.2m3.9m1.8m1.1m1.4m

Interest Paid

31.0k76.0k46.0k116.0k

Guided Therapeutics Ratios

USDY, 2019

EV/EBIT

-2.2 x

EV/CFO

-3 x